Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Prognostx Health Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and a distinct art unit. With a single pending action, the company's immediate patent strategy in this field is focused on a single application, making the outcome of this specific case the focus of the portfolio's current activity in this area.
RAMADAN, OMAR is the busiest examiner for this portfolio, handling the pending office action that constitutes the company's total pending workload. This concentration in a single art unit means the prosecution process is conducted through a single channel. Practitioners can focus their efforts on the specific requirements and historical patterns of this examiner, as no other pending matters exist to provide alternative paths for intellectual property protection at this time. Consequently, the interaction with this individual examiner will determine the success of the company's health-related patent applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAMADAN, OMAR | 1 | 25.4% | +56.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18630041 | METHOD OF DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | RAMADAN, OMAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18630041 | METHOD OF DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | RAMADAN, OMAR | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18630041 | METHOD OF DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | RAMADAN, OMAR | 1678 | §101§112 | Non-Final OA | — | Pending | Apr 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPrognostx Health Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Omar Ramadan has the most, with 1 of Prognostx Health Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
